Antiepileptogenesis, Plasticity of AED Targets, Drug Resistance, and Targeting the Immature Brain
Total Page:16
File Type:pdf, Size:1020Kb
Jasper's Basic Mechanisms of the Epilepsies Jasper's Basic Mechanisms of the Epilepsies Antiepileptogenesis, Plasticity of AED Targets, Drug resistance, and Targeting the Immature Brain Heinz Beck1 Yoel Yaari2,3 1 Department of Epileptology, Laboratory of Experimental Epileptology and Cognition Research, University of Bonn Medical Center, Sigmund-Freud Str. 25, 53105 Bonn, Germany 2 Department of Medical Neurobiology, Institute of Medical Research Israel-Canada, Hebrew University- Hadassah School of Medicine, Jerusalem, Israel 3 The Interdisciplinary Center for Neuronal Computation, the Hebrew University, Jerusalem 91904, Israel Summary Resistance to currently available antiepileptic drugs is a major problem in the treatment of temporal lobe epilepsy that affects ~30% of patients. The antiepileptic drug targets are mostly voltage-gated ion channels or neurotransmitter receptors. Manifold changes in the molecular composition and pharmacology of common antiepileptic drug targets, such as sodium channels, hyperpolarization- activated cationic ion channels and GABA receptors have been described. Available evidence suggests that plasticity of antiepileptic drug targets, with a concomitantly decreased sensitivity to antiepileptic drugs, coexists with other cellular mechanisms to cause pharmacoresistance. A better understanding of the mechanisms of pharmacoresistance is crucial for the development of new antiepileptic therapies. Introduction The cellular basis of epileptic seizures consists of high frequency, synchronized discharges of neuronal ensembles. The ultimate goal of all antiepileptic therapies is to prevent the occurrence of such episodes or to substantially attenuate their severity. To this end, a multitude of antiepileptic compounds have been developed that are currently in clinical use. However, seizures remain uncontrolled by carefully monitored drug treatment in a substantial portion (~30 %) of epilepsy patients. Therefore, a better understanding of the mode of action of different antiepileptic drugs is mandatory, along with an improved understanding of why these compounds fail in some epilepsy patients, with the ultimate goal of developing new therapeutic avenues. So far, two hypotheses have been advanced to account for the cellular basis of pharmacoresistance in chronic epilepsy. The first hypothesis proposes that pharmacoresistance involves an up-regulation of multidrug-transporters at the blood-brain barrier. This up- regulation limits the access of antiepileptic drugs to the brain parenchyma, and therefore leads to a reduced drug concentration at the respective drug target. Because multidrug transporter proteins are of central importance to this hypothesis, it has been termed the ‘transporter hypothesis’. The second hypothesis contends that the molecular targets of antiepileptic drugs are modified in chronic epilepsy. Consequently, they are less sensitive to these compounds. This hypothesis has been coined the ‘target hypothesis’.1,2 Clearly, these two hypotheses are not mutually exclusive. Rather, the underlying mechanisms may co-exist and perhaps even act in synergy. The subject of the following review article is the target hypothesis. We describe the molecular mechanisms that alter the targets of antiepileptic drugs and how these mechanisms may interact with altered drug transporter function to cause pharmacoresistance. Page 2 Defining drug targets In general, antiepileptic drug targets are proteins involved in neuronal function, which mediate a reduction in excitability after binding the antiepileptic drug at clinically relevant Jasper's Basic Mechanisms of the Epilepsies Jasper's Basic Mechanisms of the Epilepsies concentrations. A plethora of drug targets has been identified in central neurons (see Table 1). By far most of these targets are neurotransmitter receptors or voltage-gated ion channels. A comprehensive review of the different ion channel types that are affected by antiepileptic drugs is beyond the scope of this review. However, a number of classes of ion channels are particularly prominent targets. Table 1 Drug targets for common antiepileptic drugs Voltage-gated ion channels Neurotransmission INaT INaP ICa IK IH GABA Glu Presynaptic. Primarily targeting voltage-gated ion channels Phenytoin + + + + Carbamazepine + + Oxcarbazepine + + Lamotrigine + + + + + Valproic acid + +/− + + Losigamone + Retigabine + Zonisamide + + Ethosuximide − + + + Mixed mechanism Felbamate + + + + Topiramate + + + + + + Primarily affecting neurotransmitter receptors, release or metabolism Levetiracetam − − + + + (SV2A) Phenobarbital + + Benzodiazepine + Vigabatrin + Tiagabin + Other Gabapentin, primary target alpha2delta-1 subunit − − − − + − − − INaP: persistent sodium current, INaT: transient sodium current, ICa: calcium currents, IK: voltage-gated potasium currents, IH: H-current, GABA: activity on the GABAergic system, Glu: activity on the glutamatergic system. Sodium channels Voltage-gated sodium channels are implicated in the mode of action of a large number of common antiepileptic drugs, such as phenytoin, carbamazepine, valproate, lamotrigine, lacosamide and eslicarbazepine.3–5 These channels are found in all excitable cells and are Antiepileptogenesis, Plasticity of AED Targets, Drug resistance, and Targeting the Immature Brain Page 3 capable of extremely rapid channel gating that mediates millisecond scale physiological processes.6 They open rapidly upon membrane depolarization, causing the upstroke of the action potential, and subsequently undergo fast inactivation, thus contributing to its Jasper's Basic Mechanisms of the Epilepsies Jasper's Basic Mechanisms of the Epilepsies downstroke. Upon repolarization of the cell membrane, sodium channels recover from inactivation with a complex time course. In many cells, however, a non-inactivating, persistent component of the sodium current is also observed in addition to the rapidly inactivating component. This current component activates even during subthreshold depolarizations, and therefore is important in controlling subthreshold activity. Both the transient and the persistent components of the sodium current are potently inhibited by antiepileptic drugs, such as phenytoin, carbamazepine and lamotrigine, in addition to other drugs. A characteristic effect of most of these sodium channel blockers is that they preferentially bind to channels that have entered an inactivated state following depolarization of the cell. In addition, a second major mechanism is that the recovery from depolarization-induced inactivation is prolonged by many antiepileptic drugs.5,4 These two effects together explain why these drugs preferentially block repetitive high-frequency neuronal activity and long-lasting depolarizations, both of which typically occur during epileptic seizures. Calcium channels Voltage-gated calcium channels are also targets for numerous antiepileptic drugs. CNS neurons express multiple types of calcium channels, which can be separated into two classes based on their biophysical properties, namely, high-threshold and low-threshold calcium channels.7 A number of antiepileptic drugs has been shown to inhibit high threshold calcium channels in native neurons at high therapeutic concentrations.8–10 and this has been proposed to inhibit neurotransmitter release via a reduction of presynaptic action potential-induced calcium rises.11 Some antiepileptic drugs potently inhibit low-threshold (also known as T-type) calcium channels, which are expressed in postsynaptic compartments,12–14 and powerfully control postsynaptic excitability and the propensity to generate burst discharges.15 Intriguingly, the antiepileptic drug gabapentin has been shown to exhibit strong and specific binding to the accessory calcium channel alpha2delta subunit,16 but this binding seems to have no effect on the functional properties of the channel complex, suggesting that gabapentin binding to these subunits exerts effects that are not dependent on calcium channel modulation.17 HCN channels HCN channels, responsible for generating the so called H-current, are cation permeable channels that are activated by hyperpolarization and deactivate upon depolarization of the membrane potential.18,19 H-currents modulate membrane resistance and resting potential, and can mediate pacemaker activity in some types of neurons due to their particular biophysical properties.19 H-currents, and their corresponding HCN channel subunits, appear to be located mainly in dendrites.20–22 Accordingly, they potently modify dendritic integration of excitatory input.22,23 Interestingly, dendritic H-currents are potentiated by application of the antiepileptic drugs lamotrigine or Gabapentin.24,25 Thus, H-currents appear to be dendritic antiepileptic drug targets. GABAA receptors A further group of antiepileptic drugs seems to exert its main actions via an increase in synaptic inhibition. Gamma-aminobutyric acid (GABA) is the predominent inhibitory neurotransmitter in the adult brain. The ionotropic GABAA receptor, which conducts chloride upon the binding of GABA, is an important target for antiepileptic drugs. GABAA receptor-active drugs include direct modulators such as benzodiazepines and barbiturates, which increase the GABAA receptor-mediated chloride currents via allosteric modulation.26 A number of additional antiepileptic drugs indirectly enhance GABAA receptor-mediated action by inhibiting the re- Antiepileptogenesis, Plasticity of AED Targets, Drug resistance, and Targeting the Immature Brain Page 4 uptake of GABA